<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04748276</url>
  </required_header>
  <id_info>
    <org_study_id>TRAIT-MDD-107</org_study_id>
    <nct_id>NCT04748276</nct_id>
  </id_info>
  <brief_title>Tracking Response to Antidepressants in Advance of Investigational Trials</brief_title>
  <acronym>TRAIT</acronym>
  <official_title>Tracking Response to Antidepressants in Advance of Investigational Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adams Clinical</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adams Clinical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      TRAIT is an open-label observational study to evaluate treatment response to&#xD;
      selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake&#xD;
      inhibitors (SNRIs) among individuals meeting criteria for Major Depressive Disorder (MDD) and&#xD;
      seeking enrollment in investigational trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Depression Inventory - 17 item (HAM-D) total score in response to a treatment cycle from Baseline/Day 0 to the end of a 6-week treatment cycle.</measure>
    <time_frame>Up to 33 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure to respond to 1, 2, or 3+ ADT treatment cycles, as defined as &lt; 25% change in HAM-D total score from study Baseline/Day 0 to Day 42 of the participant's 1st, 2nd, or 3rd+ treatment cycles.</measure>
    <time_frame>Up to 33 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response to 1, 2, or 3+ ADT treatment cycles, as defined as ≥ 25% to &lt; 50% change in HAM-D total score from study Baseline/Day 0 to Day 42 of the participant's 1st, 2nd, or 3rd+ treatment cycles.</measure>
    <time_frame>Up to 33 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of treatment cycles required to reach ADT response, as defined as ≥ 50% reduction in HAM-D score from Baseline/Day 0 to Day 42 of each treatment cycle.</measure>
    <time_frame>Up to 33 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Presence of and change in anxiety symptoms as assessed by the MDD with Anxious Distress subscale of the Mini-International Neuropsychiatric Inventory (MINI), and self-report on the Beck Anxiety Inventory (BAI).</measure>
    <time_frame>Up to 33 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of and change in sleep-related disturbance as assessed by the self-reported Insomnia Severity Index (ISI).</measure>
    <time_frame>Up to 33 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of and change in anger symptoms as assessed by the self-reported Massachusetts General Hospital Anger Attacks Questionnaire (MGH AAQ), and the self-reported Concise Associated Symptoms Tracking Scale (CAST-SR).</measure>
    <time_frame>Up to 33 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of and change in depression-/treatment- related sexual dysfunction as assessed by the self-reported Change in Sexual Functioning Questionnaire (CSFQ).</measure>
    <time_frame>Up to 33 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of and change in functional impairment as assessed by the Sheehan Disability Scale, Inventory of Depressive Symptomology, Short Form Survey Instruments, Patient Global Impressions, and the Clinical Global Impression scale.</measure>
    <time_frame>Up to 33 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of and change in pain conditions as assessed by the self-reported Brief Pain Inventory, Short Form (BPI-SF) and Visual Analog Scale - Pain (VAS-PAIN).</measure>
    <time_frame>Up to 33 weeks</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Major Depressive Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)</intervention_name>
    <description>Protocol-approved antidepressant treatments (ADT) will be prescribed in accordance with standard of care, whenever possible following dosing recommendations within the Study Formulary and Prescribing Guidelines (Sertraline 100 mg/day; Citalopram 20 mg/day; Escitalopram 10 mg/day; Fluoxetine 20 mg/day; Paroxetine 20 mg/day; Duloxetine 60 mg/day; Buproprion 300 mg/day; Desvenlafaxine 50 mg/day; Venlafaxine 150 mg/day). ADTs may be up or down-tapered as necessary.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults who currently meet the Diagnostic and Statistical Manual - Version 5 (DSM-5)&#xD;
        criteria for Major Depressive Disorder and are seeking enrollment in an industry-sponsored&#xD;
        clinical trial of a second- or third-line antidepressant.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has signed an ICF prior to any study-specific procedures being performed.&#xD;
&#xD;
          -  Participant is male or female of age ≥ 18 years old.&#xD;
&#xD;
          -  Participant has a diagnosis of MDD as confirmed by the MINI semi-structured diagnostic&#xD;
             interview and ≥ 14 HAM-D total score.&#xD;
&#xD;
          -  Participant is in good physical health and, in the opinion of the investigator, is a&#xD;
             suitable candidate for treatment with an ADT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is pregnant, breast-feeding, or planning to become pregnant.&#xD;
&#xD;
          -  A history or presence of a clinically significant hepatic, renal, gastrointestinal,&#xD;
             cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, or&#xD;
             neurologic abnormality, which in the opinion of the investigator may impact&#xD;
             participant safety or study results.&#xD;
&#xD;
          -  Participant has a history of any psychiatric condition other than MDD, which in the&#xD;
             opinion of the investigator is primary, or any other psychiatric or neurologic&#xD;
             disorder or symptom that could pose undue risk to the participant or compromise the&#xD;
             study.&#xD;
&#xD;
          -  Any participant who represents an acute suicidal risk in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Moderate or severe substance use disorder within 90 days prior to screen, according to&#xD;
             DSM-5 criteria that in the opinion of the investigator could pose undue risk to the&#xD;
             participant, or compromise the study.&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, makes the participant&#xD;
             unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenicka Engler, PsyD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adams Clinical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenicka Engler, PsyD</last_name>
    <phone>617-744-8542</phone>
    <email>jengler@adamsclinical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Adams Clinical</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenicka Engler, PsyD</last_name>
      <phone>617-744-8542</phone>
      <email>jengler@adamsclinical.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 7, 2021</study_first_submitted>
  <study_first_submitted_qc>February 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

